Key Highlights

  • Exagen shares are trading down 9.13% at $4.58 versus a prior close of $5.04.
  • Third quarter Revenue was $18.4 million, up 7% and the best third quarter in company history.
  • Trailing 12-month average selling price reached a record $451.
  • Full-year 2026 revenue guidance of $72 million to $75 million was reiterated.
  • Test Volume grew only 2% against a tougher comparison.

Exagen (NASDAQ:XGN) is trading down 9.13% at $4.58, a Penny Stock giving back ground after third quarter results that were solid on price but slower on volume. Revenue reached $18.4 million, up 7%, the best third quarter in company history. Peer Quest Diagnostics (NYSE:DGX) is trading up 0.55%, so the decline is specific to Exagen.

Record Revenue, Flat Loss

Year-to-date revenue is up more than 11%, and adjusted EBITDA has improved by over 30%. The third quarter adjusted EBITDA loss was $1.9 million, flat with a year ago. Avise CTD revenue was $16.4 million, and pharma services revenue topped $900,000 with a Backlog of about $5.5 million.

Price Is Doing the Work

Trailing 12-month average selling price reached a record $451, up $10 from a year ago and the 14th consecutive quarter of improvement. About $800,000 was collected from claims older than 360 days, versus over $1 million in the second quarter. Management targets a price of about half the Medicare rate, or $600 to $650 per test. Gross Margin was just under 59%, with a goal of the mid-60% range over time.

Volume Growth Slows

Test volume grew 2% against a tougher comparison. Ordering physicians rose 5%, and trailing 12-month revenue per territory rose nearly 6% even as territories expanded from 42 to 45. October was described as the third-highest volume month in the last couple of years.

Guidance Reiterated, Not Raised

Full-year revenue guidance of $72 million to $75 million was reiterated. It assumes high single-digit volume growth and mid-single-digit price growth versus the fourth quarter 2025 exit rate, plus normal second-half seasonality. Management said adjusted EBITDA breakeven is expected at about $80 million of revenue with a 63% gross margin. It also said any PAMA impact on generic codes should be a low single-digit headwind.

Management said the company has the runway to reach sustainably positive adjusted EBITDA and operating cash flow.

Analysts Stay Bullish

All six analysts covering the stock are bullish, with an average target of $10.17 and a range of $9 to $12. The stock trades within a 52-week range of $2.59 to $9.74.

Volume Growth Decides Whether the Guide Holds

A 2% volume gain sits below the high single-digit growth the full-year range assumes. The fourth quarter needs faster test volume to reach the $72 million to $75 million range, and the lower end of that range implies a step up from the third quarter pace of $18.4 million.

The next markers are fourth quarter volume against that assumption, continued price gains toward the $600 to $650 target, and progress to the $80 million breakeven revenue level.